Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

被引:35
|
作者
Ng, Kennedy Yao Yi [1 ]
Tan, Sze Huey [2 ,3 ]
Tan, Jack Jie En [4 ]
Tay, Desiree Shu Hui [4 ]
Lee, Ailica Wan Xin [4 ]
Ang, Andrea Jing Shi [5 ]
Wong, Lawrence Wen Jun [6 ]
Choo, Su Pin [1 ,7 ]
Tai, David Wai-Meng [1 ,3 ]
Lee, Joycelyn Jie Xin [1 ,3 ]
机构
[1] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Div Clin Trials & Epidemiol Sci, Singapore, Singapore
[3] Duke NUS Med Sch, Oncol Acad Program, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore
[5] Singapore Gen Hosp, Div Internal Med, Singapore, Singapore
[6] KK Women & Childrens Hosp, Div Pediat, Singapore, Singapore
[7] Curie Oncol, Singapore, Singapore
关键词
Hepatocellular carcinoma; Immune checkpoint inhibitors; Immune-related adverse events; Survival; Response; PHASE-III; CANCER; SORAFENIB; ASSOCIATION; ANTI-PD-1; SURVIVAL;
D O I
10.1159/000518619
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Development of immune-related adverse events (irAEs) has been associated with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains unknown whether such an association exists in advanced hepatocellular carcinoma (aHCC). This study aims to evaluate the association between irAEs and ICI efficacy in patients with aHCC. Methods: We performed a retrospective cohort study on patients with aHCC who received at least one dose of an ICI between May 2015 and November 2019 at the National Cancer Centre Singapore. The primary study objectives were to compare the overall survival (OS) and progression-free survival (PFS) between patients with and without irAEs. Complementary multivariable landmark analyses were performed at the 6-week and 12-week landmarks. Data cutoff was December 31, 2020. Results: One hundred and sixty-eight patients were included. Median age was 69 years, 85.7% were male, 57.7% had hepatitis B infection, 60.7% had ECOG 0, and 78.0% had Child-Pugh A liver cirrhosis. 82.7% received ICI monotherapy, while 17.3% received ICI in combination. Development and severity of irAE were correlated with survival. The median PFS for grade >= 3 irAE versus grades 1-2 irAE versus no irAE was 8.5 versus 3.6 versus 1.3 mths (p < 0.001). The median OS for grade >= 3 irAE versus grades 1-2 irAE versus no irAE was 26.9 versus 14.0 versus 4.6 mths (p < 0.001). Patients with >= 2 irAEs had a significantly longer OS on multivariable analysis (adjusted hazard ratio [aHR]0.35, p < 0.001). The presence of grade >= 3 irAEs was associated with a significantly longer OS on the multivariable analysis at the 6-week landmark (aHR0.34, p = 0.030) and 12-week landmark (aHR0.28, p = 0.011). The use of systemic corticosteroids in patients with irAE was associated with a trend toward a longer OS (20.7 vs. 14.3 mths, p = 0.064). Conclusion: Our study suggests that the presence of all-grade irAEs may be a potential prognostic biomarker in patients with aHCC treated with ICI. Patients with more severe irAEs and multisystem involvement have better prognosis. The prompt use of systemic corticosteroids to treat patients with irAEs is key to ensure the best long-term outcomes for these patients.
引用
收藏
页码:9 / 21
页数:13
相关论文
共 50 条
  • [1] Letter regarding "Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma"
    Wang, Yinhan
    Huang, Yongfa
    Yang, Huayu
    Mao, Yilei
    [J]. LIVER CANCER, 2023, 12 (01) : 85 - 86
  • [2] Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
    Wong, L.
    Ang, A.
    Ng, K.
    Tan, S. H.
    Choo, S. P.
    Tai, D.
    Lee, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [3] IMMUNE-RELATED ADVERSE EVENTS FOLLOWING IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Zhu, Kaiwen
    Niu, Chengu
    Liu, Hongli
    Okolo, Patrick
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1431 - S1432
  • [4] Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
    Xu, Shuo
    Lai, Ruixue
    Zhao, Qian
    Zhao, Pandong
    Zhao, Ruili
    Guo, Zhanjun
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [5] Immune-Related Adverse Events of Immune Checkpoint Inhibitors
    Ramos-Casals, Manuel
    Siso-Almirall, Antoni
    [J]. ANNALS OF INTERNAL MEDICINE, 2024, : ITC17 - ITC32
  • [6] The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
    Fukushima, Taito
    Kobayashi, Satoshi
    Ueno, Makoto
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (09) : 949 - 958
  • [7] Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
    Zhong, Li
    Wu, Qing
    Chen, Fuchun
    Liu, Junjin
    Xie, Xianhe
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2559 - 2576
  • [8] Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
    Li Zhong
    Qing Wu
    Fuchun Chen
    Junjin Liu
    Xianhe Xie
    [J]. Cancer Immunology, Immunotherapy, 2021, 70 : 2559 - 2576
  • [9] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Immune-related adverse events of checkpoint inhibitors
    Ramos-Casals, Manuel
    Brahmer, Julie R.
    Callahan, Margaret K.
    Flores-Chavez, Alejandro
    Keegan, Niamh
    Khamashta, Munther A.
    Lambotte, Olivier
    Marlette, Xavier
    Prat, Aleix
    Suarez-Almazor, Maria E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)